With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59878-57-8,1-(Cyclopropylcarbonyl)piperazine,as a common compound, the synthetic route is as follows.
59878-57-8, Step 2: N-[4-(4-Cyclopropanecarbonyl-piperazin-l-yl)-benzyl]-N-isobutyl-C-phenyl- methanesulfonamide In a vial, N-[(4-bromophenyl)methyl]-N-isobutyl-l-phenyl-methanesulfonamide (53 mg, 0.13 mmol), 2-dicyclohexylphosphino-2′,6′-di-i-propoxy-l, r-biphenyl (3.2 mg, 0.0067 mmol) , chloro(2-dicyclohexylphosphino-2′,6′-di-i-propoxy- 1 , 1 ‘-biphenyl)[2-(2 aminoethylphenyl)]palladium(II), methyl-t-butylether adduct (6 mg, 0.0067 mmol) and sodium teri-butoxide (20 mg, 0.20 mmol) were combined and the vial was purged with nitrogen. 1,4-Dioxane (1 mL) and cyclopropyl(piperazin-l-yl)methanone (31 mg, 0.20 mmol) were then added and the reaction was stirred at ambient temperature for 16 hours. The reaction was then partitioned between water and dichloromethane and the dichloromethane layer was isolated with a phase separator cartridge, concentrated and purified by preparative reverse phase HPLC to yield 27 mg of N-[4-(4- cyclopropanecarbonyl-piperazin-l-yl)-benzyl]-N-isobutyl-C-phenyl- methanesulfonamide. 1H NMR (400 MHz, DMSO) delta 7.38 – 7.34 (m, 5H), 7.21 (d, J = 8.5 Hz, 2H), 6.94 (d, J= 6.8 Hz, 2H), 4.40 (s, 2H), 4.16 (s, 2H), 3.82 – 3.78 (m, 2H), 3.62 – 3.58 (m, 2H), 3.20-3.05 (m, 4H), 2.80 (d, J= 7.5, 2H), 2.12 – 1.92 (m, 1H), 1.60- 1.45 (m, 1H), 0.83 – 0.69 (m, 4H), 0.67 (d, J= 7.1 Hz, 6H); LCMS (m/z) ES+470.2 [M+l]+.
59878-57-8 1-(Cyclopropylcarbonyl)piperazine 2064235, apiperazines compound, is more and more widely used in various fields.
Reference：
Patent; F. HOFFMANN-LA ROCHE AG; FAUBER, Benjamin; RENE, Olivier; WO2013/92941; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics